Verve Therapeutics, Inc.

As of March 2, 2023, Verve Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, despite a strong year-to-date return of 97.34%, while its long-term performance remains poor with a three-year return of -63.64%.

As of March 2, 2023, Verve Therapeutics, Inc. is considered a risky investment due to its negative financial metrics, including a negative P/E ratio and a ROE of -38.58%, indicating it is overvalued compared to peers like ADMA Biologics, Inc. which has a P/E ratio of 21.68.

As of June 17, 2025, the trend is mildly bullish due to a bullish MACD and Bollinger Bands, despite a bearish weekly RSI and mixed signals from moving averages and KST, indicating a cautious bullish outlook.

Verve Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $33 million and a net loss of $31 million. It has a market cap of approximately $1.02 billion and does not pay dividends.

As of Jun 18, Verve Therapeutics, Inc. has a market capitalization of 1,015.98 million and reported net sales of 59.62 million with a net profit of -180.99 million over the latest four quarters. Shareholder's funds are 493.40 million, and total assets amount to 647.39 million.